Arqule Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016      No Of Pages (47)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Arqule-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arqule. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Arqule-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Arqule-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arqule. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Arqule-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Arqule

  1.1 Business Overview

  1.2 Arqule Pipeline Overview

 

2. Arqule Cancer Drugs in Research Phase

  2.1 Cancer Therapeutics - ArQule/Beryllium

 

3. Arqule Cancer Drugs in Preclinical Phase

  3.1 ARQ 531

  3.2 RAF kinase Inhibitors - ArQule

 

4. Arqule Cancer Drug in Clinical Phase

  4.1 Tivantinib Companion Diagnostic - ArQule/Daiichi Sankyo

 

5. Arqule Cancer Drugs in Phase-I

  5.1 ARQ 751

  5.2 ARQ 092

 

6. Arqule Cancer Drugs in Phase-II

  6.1 ARQ 087

  6.2 ARQ 761

 

7. Arqule Cancer Drugs in Phase-III

  7.1 Tivantinib

 

8. No Development Reported in Cancer Drugs in Clinical Pipeline

  8.1 CSP Inhibitors - ArQule

  8.2 Histone Deacetylase Inhibitors - ArQule

  8.3 Beta Lapachone Conjugates - ArQule

  8.4 p53 Upregulated Modulator Of Apoptosis Stimulants - ArQule

  8.5 Heat Shock Protein 90 Inhibitors - ArQule

  8.6 Cell Cycle Checkpoint Activators - ArQule

 

 9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 Beta Lapachone

  9.2 ARQ 621

  9.3 ARQ 736

  9.4 ARQ 171


Figure 1 1: Arqule Cancer Pipeline by Phase (%)

Figure 1 2: Arqule Cancer Pipeline by Phase (Number)

Figure 1 3: Arqule Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1 4: Arqule Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)